ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 518

Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis

Sulé Gunter1, Lebogang Mokotedi2, Monica Gomez2, Linda Tsang2, Aletta Millen3 and Patrick Dessein2, 1Depeartment of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, 2Department of Health Sciences, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, 3Department of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adipocytokines, Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The rheumatoid arthritis (RA) population demonstrate a significantly increased incidence of cardiac events. Cardiac dysfunction in RA may occur as a result of impaired filling during diastole, or as contractile insufficiency (systolic dysfunction). Chronic systemic inflammation may be the underlying cause of cardiac alterations, and also impact significantly on traditional cardiovascular risk profiles. Apelin is an endogenous peptide known for its vasoactive effects, inotropic action and general cardioprotective function. Apelin may prove to be particularly beneficial within the RA population.

This study aimed to determine the association of apelin concentrations with measures of cardiac geometry, systolic and diastolic function, independent of traditional risk factors and inflammation in RA patients.

Methods:

186 RA patients where included, where demographic, anthropometric and RA disease characteristics were recorded. Cardiac structure and function was assessed using two-dimensional directed M-mode echocardiography, Pulsed Doppler, and tissue Doppler imaging. Circulating cytokine concentrations were determined using immunoturbidimetric methods. Apelin-13 concentrations were quantified using a solid-phase sandwich ELISA technique. The association of apelin concentrations with stroke volume, ejection fraction, endocardial and midwall fractional shortening, relative wall thickness, left ventricular mass, mitral inflow (E/A), lateral and septal e’, left ventricular filling pressures (E/e’), and left atrial volume index (LAVI) were determined in comprehensively adjusted multivariate and backward regression analyses.

Results:

Apelin concentrations were not independently associated with cardiac geometry, diastolic or systolic function (p>0.05) in all patients. Body mass index impacted on apelin-ejection fraction and apelin-fractional shortening relations (interaction p=0.02, for both), and hypertension impacted on apelin-E/A ratio, apelin-stroke volume, apelin-ejection fraction, apelin-endocardial fractional shortening and apelin-midwall fractional shortening relations (interaction p=0.03, p=0.01, p=0.02, p=0.01 and p=0.03, respectively). In stratified analyses, apelin was associated with improved ejection fraction and endocardial fractional shortening in patients with a BMI ≥ 25kg/m2, but not in those with a BMI < 25 kg/m2. Apelin concentrations were associated with an improved E/A ratio (partial r=0.31; p=0.04), stroke volume (partial r=0.29; p=0.03), ejection fraction (partial r=0.39; p=0.01), endocardial fractional shortening (partial r=0.40; p=0.003) and midwall fractional shortening (partial r=0.31; p=0.02) in hypertensive but not normotensive patients.

Conclusion:

Apelin concentrations are associated with improved active relaxation in hypertensive patients only. The inotropic effects of apelin is paradoxically increased in the presence of adverse metabolic risk factors. The vasoactive and cardioprotective effects of apelin may be particularly beneficial in those with adverse cardiometabolic risk profiles.


Disclosure: S. Gunter, None; L. Mokotedi, None; M. Gomez, None; L. Tsang, None; A. Millen, None; P. Dessein, None.

To cite this abstract in AMA style:

Gunter S, Mokotedi L, Gomez M, Tsang L, Millen A, Dessein P. Cardiometabolic Risk Factors Impact on the Cardioprotective Effect of Apelin on Systolic and Diastolic Function, in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiometabolic-risk-factors-impact-on-the-cardioprotective-effect-of-apelin-on-systolic-and-diastolic-function-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiometabolic-risk-factors-impact-on-the-cardioprotective-effect-of-apelin-on-systolic-and-diastolic-function-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology